Biologics Prescribing for Rheumatoid Arthritis in Older Patients: A Single-Center Retrospective Cross-Sectional Study.

Item

http://www.wikidata.org/entity/Q36943015

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Biologics Prescribing for Rheu ...... pective Cross-Sectional Study.

@en

type

Item

label

Biologics Prescribing for Rheu ...... pective Cross-Sectional Study.

@en

prefLabel

Biologics Prescribing for Rheu ...... pective Cross-Sectional Study.

@en

P1476

Biologics Prescribing for Rheu ...... pective Cross-Sectional Study.

@en

P2093

Alan Steuer

http://www.w3.org/2001/XMLSchema#string

Klara Morsley

http://www.w3.org/2001/XMLSchema#string

Thomas Kilner

http://www.w3.org/2001/XMLSchema#string

P2860

Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study.

Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study

Mortality in rheumatoid arthritis: 2008 update.

Glucocorticoids and rheumatoid arthritis: back to the future?

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

Long term safety of etanercept in elderly subjects with rheumatic diseases.

Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?

Time trends in medication use and expenditures in older patients with rheumatoid arthritis

A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers

Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety.

P2888

s40744-015-0021-z

P304

165-172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40744-015-0021-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284805810

http://www.w3.org/2001/XMLSchema#string

P698

27747537

http://www.w3.org/2001/XMLSchema#string

P932

4883268

http://www.w3.org/2001/XMLSchema#string